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Abstract 
 
 Objective: Autoantigen-specific immunotherapy by means of mucosal tolerance 
induction via the intranasal route is an attractive therapeutic option for the treatment of 
autoimmune diseases, including rheumatoid arthritis (RA). Human Cartilage 
glycoprotein-39 (HC gp-39) has been identified as a potential key autoantigen in RA. 
Based on animal studies, intranasal administration of the autoantigen is hypothesized to 
induce immunological tolerance in RA patients and to ameliorate disease activity. In a 
Phase I/IIA clinical trial in RA patients, intranasal application of HC gp-39 was safe and 
well tolerated. The current paper describes the first large clinical study investigating the 
efficacy of intranasally administered fully human, recombinant HC gp-39 (Org 39141). 
  
 Methods: In a 13-wk multicenter, double-blind, randomized, placebo-controlled, 
parallel group, dose-finding, Proof-of-Concept trial, patients with RA (DMARD naïve or 
following wash-out of DMARD therapy) were randomized to receive either intranasal 
applications of placebo or HC gp-39 in doses of 30, 150, 300 or 600 micrograms, once 
per week. The primary efficacy variable was the DAS28. 
  
 Results: During the treatment period the DAS28 decreased similarly for all 
treatment groups - including placebo - indicating lack of efficacy of intranasal HC gp-39 
therapy in the current setting. Safety variables were similar for all study groups.  
  
 Conclusion: It was concluded that, with the use of the chosen treatment protocol 
(dose levels and frequency of dosing), intranasal treatment with Org 39141 was safe 
but did not result in clinical improvement different from that seen in placebo-treated 
patients. 
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Introduction 
 Despite new treatment modalities and more intensive therapeutic strategies, in 
most cases rheumatoid arthritis (RA) remains a chronic and progressive disease. The 
challenge for novel therapies is to specifically inhibit immune cells initiating and 
perpetuating RA-related inflammation and tissue destruction and to change the disease 
without causing severe side effects and/or general immunosuppression. Autoantigen-
specific immunotherapy by means of mucosal tolerance induction is an attractive option 
potentially fulfilling the above mentioned challenge. Oral tolerance targeting type II 
collagen has been tested in animal models and clinical settings, clinical trials with RA 
patients showing mixed results.[1-2] Currently, administration of antigens via the nasal 
mucosa is regarded as the most powerful route for induction of immunological 
tolerance.[3]  
 Human Cartilage glycoprotein-39 (HC gp-39) has been identified as a potential 
key autoantigen in RA.[4, 5] Epitopes of HC gp-39 are recognized by peripheral blood 
mononuclear cells of RA patients.[4] HC gp-39 protein was detected in RA synovial 
tissue and its epitopes are presented by antigen presenting cells in inflamed joints of RA 
patients.[6-8] The relevance of HC gp-39 in joint pathology was strongly supported by 
the demonstration that HC gp-39 induces arthritis in Balb/c mice. HC gp-39 was shown 
to significantly reduce clinical symptoms of arthritis when administered intranasally after 
disease had developed in this model.[4] HC gp-39 was able to modulate arthritis in the 
collagen-induced arthritis model (DBA/1 mice) as well, showing cross-tolerance 
presumably mediated by bystander suppression.[5] Thus, intranasal treatment with HC 
gp-39 can potentially modify and control arthritis offering an opportunity for 
development as a therapy for RA.  
 These preclinical results were followed by a Phase I/IIA study investigating the 
intranasal route in RA for the first time.[9] Overall, the investigational drug 
(recombinant HC gp-39 (Org 39141)) was well tolerated. In the pooled placebo 
patients, a decrease in DAS28 was observed, but to a lesser extent than in the Org 
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39141-treated patients. It was concluded that the observed safety and trend towards 
efficacy warrant further clinical development of Org 39141.[9]  
 The parallel group, dose-finding trial described here succeeded the Phase I/IIA 
study and was the first large clinical investigation into the efficacy of a fully human, 
recombinant protein (HC gp-39) administered via the nasal route with the therapeutic 
objective to re-establish immunological tolerance and to ameliorate disease activity in 
rheumatoid arthritis.  
 
Patients and Methods 
Trial Protocol and Informed Consent 
 The protocol and informed consent form were approved by the institutional 
ethics committees of the 16 participating rheumatology hospitals. All patients had given 
written consent for the study and for publication of the results. 
Patients  
 Patients were selected from the outpatient population of 16 rheumatology clinics 
in The Netherlands and Belgium (acknowledgements). Inclusion criteria defined 
selection of patients having an age of 18 years or older; being diagnosed to have RA 
(most patients fulfilling ACR criteria) according to a rheumatologist; have active poly-
arthritis defined as a Modified Disease Activity Score (DAS28) of over 4.5 [10], 
belonging to one of the following two types: 1/ patients having failed treatment on 1-3 
DMARDs after at least one month of treatment on the failing DMARD or 2/ patients 
having never been treated with a DMARD. 
 
Trial design and investigational drug 
 The trial was a randomized, double-blind, placebo-controlled, parallel group, 
multi-center, dose-finding study investigating safety and efficacy of thirteen weeks of 
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once weekly intranasal administration of Org 39141. To be able to estimate the 
absolute magnitude of the effect of Org 39141 and to reveal its efficacy and adverse 
events, active treatment was compared to placebo. Patients received either placebo, or 
Org 39141 in a dose of 30, 150, 300 or 600 micrograms once per week. 
 Org 39141 - the investigational drug - is fully human recombinant HC gp-39. It 
was produced by culture of a Chinese hamster ovary (CHO) cell line in protein-free 
medium by the sponsor of this trial, NV Organon (Schering-Plough), Oss, The 
Netherlands. Org 39141 is to be regarded identical to natural HC gp-39, isolated from 
human milk. A dose was supplied as a nasal spraying system containing 1100 μl 
solution of Org 39141 in an aqueous buffer containing sodium citrate, sucrose, Tween-
20 and water for injection. Placebo vials for nasal spray consisted of the same buffer 
and were indistinguishable in appearance, shape, smell and taste from the Org 39141 
containing sprays.  Upon careful instruction by the investigator, doses were to be 
administered by patients themselves by applying two puffs of 100 μL into each nostril.  
 During the trial, no RA treatment (including DMARDs; mandatory wash-out 
period of 4 weeks) was allowed except oral glucocorticoids up to 7.5 mg/day 
prednisone or equivalent (stable dose from at least four weeks before the baseline visit) 
and NSAIDs provided that the dosage was not changed after the screening visit. 
 
Safety assessments  
 Safety data were obtained on all, outpatient clinic, visits: baseline, week 5, week 
9 and week 14. Safety assessments included adverse events, examination of the 
application site, i.e. the nose cavities, by an ENT specialist, physical examination, and 
routine laboratory testing (hematology, biochemistry and urinalysis). Additionally, 
possible serum antibodies against Org 39141 were measured.  
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Efficacy assessments  
 The primary efficacy variable was the DAS28.[10] Secondary efficacy variables 
included EULAR response outcome, ACR20 response outcome[11], individual variables 
of the ACR core set (tender and swollen joint counts (28 joints), patient’s assessment of 
pain (using a VAS scale of 0-100 mm), patient’s global assessment of disease activity 
(VAS), physician’s global assessment of disease activity (VAS), physical function (the 
Health Assessment Questionnaire, HAQ[12]), acute phase reactant (Westergren 
erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) serum level)), 
duration of morning stiffness and Sharp-van der Heijde score (radiography of both 
hands/wrists and feet). All efficacy variables were assessed at each visit except for 
radiography, assessed at baseline and week 14 visits only. Serum levels of Org 39141
 
(i.e. the Org 39141 that possibly entered the circulation via the nose or oropharynx plus 
the - from Org 39141 indistinguishable - endogenous HC gp-39) were measured in 
order to assess systemic exposure. 
 
Statistical analysis  
 Safety analyses were based on the all-patients-treated population. Adverse 
events were analyzed using patient incidence rates and were summarized by WHO 
Adverse Reaction Dictionary (version 1997.2 using system organ classes and preferred 
terms) for each treatment group. In addition, for laboratory parameters, the number of 
values outside pre-defined safety limits was determined.  
 Efficacy analyses were based on the intent-to-treat (ITT) population (i.e. all 
randomized patients who had at least one post-baseline assessment for the primary 
efficacy variable) and the per-protocol (PP) population (i.e. the ITT population minus 
the patients who had had a major protocol violation (e.g. less than 80% study 
medication compliance) as decided before unblinding). The effect of treatment was 
tested at Endpoint, that is using data from the last post-baseline visit of a patient 
(combining data of Day 92 (from patients who completed the trial) and data from visits 
before Day 92 (from patients who discontinued earlier)), using an Analysis of 
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Covariance (ANCOVA) model, with as dependent variable the primary outcome 
measure, DAS28, and as explanatory variables the baseline DAS28, and the factors 
treatment, hospital, Rheumatoid Factor (RF) present/not present, and pre-trial DMARD 
use yes/no. Pairwise comparisons between the dose-groups and the placebo group 
were made by means of Dunnett-adjusted tests. In this article, these efficacy results 
are presented with Dunnett-adjusted 95% Confidence Intervals (CI) for the differences, 
while all other efficacy measures – secondary outcomes – are presented with 
descriptive statistics.  
 
Results 
Patients data sets  
 In total 297 RA patients were randomized into five parallel treatment groups. 
Several patients discontinued prematurely because of the following reasons that were 
evenly distributed over the five treatment groups: adverse events (2.1%), lack of 
efficacy (18.5%), other reasons (4.8%). Sixty-three of the patients who had started 
treatment and had at least one post-baseline efficacy measure (i.e. 21.7% of the 
intent-to-treat data set) were excluded from the Per Protocol patient data set because 
of a major protocol violation (mainly consisting of the use of DMARDs after start of 
wash-out, deviation of in- or exclusion criteria and non-compliance for the study 
medication). It is highly unlikely that non-evaluable patients have been of influence to 
the outcome of the study, as the reasons for the major protocol violations were diverse 
and since these patients were rather equally distributed over the various treatment 
groups. 
 
Demographics, patient RA characteristics and treatment compliance 
 The demographics and patient characteristics were evenly distributed over the 
five treatment groups (Table 1). Compliance (recorded using a medication diary) was 
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relatively good; 86.3% of all planned nasal sprays were taken by the intent-to-treat 
population, while compliance was 90.6% for the per-protocol population. 
 
Efficacy 
 During the treatment period, the primary efficacy measure, the DAS28, 
decreased for all treatment groups similarly (see Table 2 for Baseline and Endpoint 
values). Superiority in efficacy of Org 39141 with respect to placebo is not proven by 
the analysis results (that included ordinary means and standard deviations, an ANCOVA 
model and multiple exploratory analyses testing various factors). None of secondary 
efficacy measures – ACR20/50/70, EULAR, individual ACR core set variables, morning 
stiffness - revealed a significant difference between an Org 39141 group and the 
placebo group (data on file). Radiography of both hands and feet, scored by means of 
the Modified Sharp-Van der Heijde score, showed on average a slight increase (i.e. 
more joint destruction) during the 14 weeks of the trial, but no significant differences 
between any of the Org 39141 treatment groups and the placebo group were observed 
(data on file). None of the extensive explorative analyses (i.e. effect of corticosteroid or 
NSAID use at baseline, DAS28 level at baseline, smoking, HC gp-39 dimorphism, RA 
duration, HLA-DR type, presence of rheumatoid factor, pre-trial DMARD use, and 
combination of pre-trial DMARD use and presence of rheumatoid factor) resulted in the 
identification of subgroups for which the treatment would be more effective compared 
to placebo. 
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Table 1 Demographics and patient RA characteristics 
 
   
Org 39141 treatment group, μg/week  
Intent-to-treat groups 
Placebo 
(N=59) 
30 μg 
(N=57) 
150 μg 
(N=58) 
300 μg 
(N=60) 
600 μg 
(N=56) 
Total 
(N=290) 
Gender   Female % 68 67 72 57 70 67 
Age  
(yr) 
 
Mean 
 
58.6 
 
53.3 
 
57.3 
 
55.0 
 
57.1 
 
56.3 
Body Mass Index 
(kg/m
2
)  
 
Mean 
 
25.9 
 
25.8 
 
26.5 
 
26.0 
 
26.9 
 
26.2 
RA duration since 
onset symptoms (yr) 
 
Mean 
 
5.2 
 
4.9 
 
5.9 
 
5.8 
 
6.3 
 
5.6 
RA duration since 
diagnosis (yr) 
 
Mean 
 
3.5 
 
3.4 
 
4.3 
 
3.6 
 
4.6 
 
3.8 
Rheumatoid factor 
positive at screening 
 
% 
 
73.7 
 
70.4 
 
71.9 
 
74.5 
 
71.4 
 
72.4 
RA functional class 
at screening         I 
                          II 
                         III   
 
% 
% 
% 
 
11.9 
76.3 
11.9 
 
22.8 
70.2 
7.0 
 
22.4 
56.9 
20.7 
 
16.7 
65.0 
18.3 
 
17.9 
67.9 
14.3 
 
18.3 
67.2 
14.5 
Shared epitope 
present* 
 
% 
 
68.4 
 
61.4 
 
75.4 
 
74.6 
 
69.6 
 
69.9 
At screening: 
- DMARD naïve 
- DMARD failure 
 
% 
% 
 
39.0 
61.0 
 
38.6 
61.4 
 
36.2 
63.8 
 
38.3 
61.7 
 
41.1 
58.9 
 
38.6 
61.4 
Concomitant <10mg 
oral corticosteroids 
 
% 
 
28.8 
 
28.1 
 
27.6 
 
28.3 
 
16.1 
 
25.9 
Concomitant NSAIDs % 
76.3 84.2 77.6 81.7 78.6 79.7 
* 
patients were considered positive for the shared epitope if the QKRAA, QRRAA or RRRAA motif was 
present in one or both class II alleles, i.e. if the HLA-DRB1 was typed 0101, 0102, 0104, 0401, 0404, 
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0405, 0408, 0409, 0410, 0413, 0416, 0419, 0421, 1001, 1113, 1402, 1406, 1409, 1413, 1417, 1419, 
1420, or 1421. Patients with typing 04011 – which is a subtyping of 0401 – were also considered positive 
for the shared epitope. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Treatment effect on the DAS28 and the ACR core set 
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Mean (SD) 
Org 39141 treatment group, μg/week  
 
ITT population 
PP population 
Placebo 
N=59 
N=44 
30 μg  
N=57  
N=40 
150 μg  
N=58  
N=43 
300 μg  
N=60  
N=50 
600 μg 
N=56  
N=50 
Total 
N=290 
N=227 
Baseline DAS28 
ITT/ PP population 
5.9 (1.2)/ 
5.8 (1.2) 
5.9 (1.0)/ 
5.9 (1.0) 
5.8 (1.3)/ 
5.7 (1.4) 
5.7 (0.9)/ 
5.7 (1.0) 
6.0 (1.0)/ 
6.1 (1.0) 
5.9 (1.1)/ 
5.8 (1.1) 
DAS28 at Endpoint* 
{Dunnett p-value for 
difference to 
placebo} 
ITT/ PP population 
5.1 (1.8)/ 
 
5.2 (1.6) 
 
5.3 (1.5) 
{0.97}/ 
5.3 (1.3) 
{0.99} 
5.4 (1.6) 
{0.66}/ 
5.5 (1.5) 
{0.45} 
5.2 (1.5) 
{0.93}/ 
5.1 (1.6) 
{0.96} 
5.5 (1.6) 
{0.84}/ 
5.4 (1.4) 
{1.00} 
5.3 (1.6) 
 
5.3 (1.5) 
 
Tender joint counts, 
based on 28 joints 
Baseline/ Endpoint* 
PP population 
 
12.2 (7.1)/ 
9.6 (7.6) 
 
11.9 (11.0)/  
8.5 (6.7) 
 
10.3 (6.2)/ 
10.2 (7.3) 
 
12.3 (7.3)/ 
8.9 (7.9) 
 
12.2 (6.5)/ 
9.1 (7.8) 
 
11.8 (6.7)/ 
9.3 (7.5) 
Swollen joint counts, 
based on 28 joints 
Baseline/ Endpoint* 
PP population 
 
10.8 (4.1)/ 
8.4 (5.8) 
 
11.5 (4.8)/ 
9.5 (6.2) 
 
10.8 (5.6)/ 
10.1 (6.4) 
 
10.2 (4.2)/ 
8.6 (6.2) 
 
12.0 (5.4)/ 
9.4 (5.9) 
 
11.0 (4.9)/ 
9.2 (6.1) 
Patient’s assessment 
of pain** 
Baseline/ Endpoint* 
PP population 
 
56.0 (20.6)/ 
50.5 (29.0) 
 
56.8 (18.3)/ 
51.9 (24.3) 
 
56.8 (22.5)/ 
53.4 (25.6) 
 
61.2 (18.6)/ 
53.1 (25.7) 
 
61.2 (19.4)/ 
51.7 (26.2) 
 
58.6 (19.9)/ 
52.1 (26.0) 
Patient’s global 
assessment of 
disease activity** 
Baseline/ Endpoint* 
PP population 
 
 
57.2 (21.1)/ 
50.0 (26.7) 
 
 
62.4 (19.3)/ 
52.7 (21.8) 
 
 
60.4 (21.3)/ 
56.1 (26.2) 
 
 
64.5 (17.8)/ 
54.5 (26.1) 
 
 
63.8 (18.3)/ 
50.5 (25.9) 
 
 
61.8 (19.6)/ 
52.7 (25.4) 
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Physician’s global 
assessment of 
disease activity** 
Baseline/ Endpoint* 
PP population 
 
56.8 (19.9)/ 
47.3 (25.5) 
 
56.8 (17.8)/ 
50.7 (21.2) 
 
53.1 (17.9)/ 
51.2 (23.9) 
 
57.4 (16.1)/ 
50.7 (25.3) 
 
58.8 (17.0)/ 
49.0 (22.5) 
 
56.7 (17.7)/ 
49.8 (23.6) 
HAQ-scores 
Baseline/ Endpoint* 
PP population 
 
0.99 (0.72)/ 
1.05 (0.85) 
 
0.93 (0.57)/ 
0.82 (0.67) 
 
1.07 (0.71)/ 
1.05 (0.82) 
 
1.05 (0.71)/ 
0.88 (0.71) 
 
1.24 (0.69)/ 
1.12 (0.82) 
 
1.07 (0.69)/ 
0.99 (0.78) 
ESR (mm/hr) 
Baseline/ Endpoint* 
PP population 
 
32.0 (22.4)/ 
31.6 (23.8) 
 
32.9 (22.4)/ 
31.2 (19.1) 
 
32.6 (21.5)/ 
31.9 (24.1) 
 
25.2 (15.8)/ 
27.4 (15.5) 
 
34.0 (18.2)/ 
36.4 (19.8) 
 
31.2 (20.1)/ 
31.7 (20.6) 
CRP (mg/L) 
Baseline/ Endpoint* 
PP population 
 
16.7 (27.4)/ 
16.9 (25.2) 
 
14.9 (16.3)/ 
16.9 (24.4) 
 
18.9 (23.9)/ 
18.3 (21.4) 
 
14.3 (18.5)/ 
13.2 (16.9) 
 
21.3 (29.0)/ 
22.5 (34.5) 
 
17.3 (23.6)/ 
17.6 (25.3) 
 
Duration of morning 
stiffness (hh:mm) 
Baseline/ Endpoint* 
PP population 
 
1:37 (1:31)/ 
1:50 (2:18) 
 
2:14 (3:44)/ 
1:48 (3:48) 
 
1:55 (1:44)/ 
2:09 (3:53) 
 
1:55 (1:51)/ 
1:26 (1:30) 
 
1:34 (1:26)/ 
1:14 (1:19) 
 
1:50 (2:09)/ 
1:40 (2:42) 
 
 
* Endpoint is a summary of the data of the last post-baseline visit of a patient (combining data of Day 92 
(from patients who completed the trial) and data from visits before Day 92 (of patients who discontinued 
earlier)); ** VAS scores of 0-100 
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Safety  
 Overall, the treatment with Org 39141 or placebo was considered to be well 
tolerated and safe. Serious adverse events (SAEs), none of which related to the study 
treatment according to the investigator, were reported for 11 patients (3.8%). No 
patients died during the trial. Of the 292 treated (at least one nasal spray) patients, 143 
patients (49.0%) experienced at least one adverse event (AE). In total, 45 patients had 
AEs that were considered possibly, probably or definitely related to the study treatment 
by the involved study physician. Fifteen patients suffered from at least one AE or SAE of 
severe intensity. In total, six patients discontinued from the trial due to SAEs (4 
patients) or AEs (2 patients); most of these patients suffered from an exacerbation of 
their RA. The most frequently reported AEs were upper respiratory tract infection 
(7.9%) and headache (5.5%). Thirteen patients experienced application site (i.e. the 
nostril) reactions. No notable differences in nature and incidence of AEs were observed 
between the treatment groups. 
 
Discussion 
 Upon completion of a Phase I/IIA study[9], a Phase IIB, dose-finding, trial was 
initiated with intranasal administration of fully human recombinant HC gp-39 protein 
(Org 39141), in an aqueous formulation containing sodium citrate, sucrose, and Tween-
20, as treatment for RA. It was the first large clinical investigation into the efficacy of 
Org 39141 administered via the nasal route with the purpose to induce immunological 
tolerance (the only therapy based on mucosal tolerance having reached Phase III being 
oral therapy with bovine collagen type II[1,13]). The current trial compared nasal 
administration of Org 39141 with placebo (vehicle only) as monotherapy in RA patients 
with a baseline DAS28 of over 4.5 using a 13 week dosing regimen of once weekly 
administration of one dose out of the range of 30-600 µg Org 39141. In the selected 
population (DMARD failure (wash-out was applied) and DMARD naïve patients), the 
chosen dosing regimen of intranasal administration of Org 39141 did not show 
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superiority in efficacy over placebo in clinical outcomes nor in biomarkers. Org 39141 
was generally well tolerated and no notable differences in nature and incidence of AEs 
were observed between the treatment groups and placebo. 
 RA treatment modalities that selectively target tissue- or antigen-specific immune 
responses are hypothesized to lack general immunosuppressive properties and related 
safety problems (infections). Autoantigen-specific immunotherapy by means of mucosal 
tolerance induction potentially represents such an antigen-specific treatment.[1-2] 
Human Cartilage glycoprotein-39 (HC gp-39) has been identified as a potential key 
autoantigen in RA.[4, 5] The therapeutic approach presented builds on mucosal 
tolerance induction and on establishing bystander suppression. Bystander suppression is 
cross-tolerance driven by autoantigen-specific T regulatory cells generated by the 
administration of autoantigen (HC gp-39) on mucosa (involving locoregional lymph 
nodes [14]), resulting in immune suppression at the site where such T regulatory cells 
encounter their antigen. This suppression not only involves the autoantigen for which 
the T regulatory cells are specific, but the local spread of suppressing cytokines also 
results in suppression of cells specific for other autoantigens that happen to be in the 
neighborhood. Intranasal application of HC gp-39 in arthritis elicited by collagen type II 
showed proof for bystander suppression (cross-tolerance) and resulted in minimal 
disease activity and joint destruction.[5] From a treatment safety point of view, 
potential side effects of bystander suppression are relevant. In case bystander 
suppression would occur in humans, this might result in local - and not general – 
downmodulation of immunological responses at sites of autoantigen (HC gp-39) 
expression: the inflamed joint. As such, this bystander suppression should be of 
additional benefit to RA patients. 
 The present study, exploring mucosal tolerance induction using intranasal 
administration of Org 39141, did not demonstrate efficacy. Several factors may have 
contributed to this failure including but not limited to the design of the study, the choice 
of the autoantigen and the route of administration, the dose and frequency of antigen 
administration, the potential interaction with other treatments (such as NSAIDs and 
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prednisone [15]), local antigen exposure and the feasibility of restoring tolerance in 
humans. 
 The original attempts of tolerance induction with oral administration of collagen 
type II as well as the present approach using nasal application of an autoantigen failed 
to show definitive treatment efficacy. Possibly, re-establishing peripheral tolerance (for 
autoantigens) is not feasible in humans. Alternatively, although it may be at the basis of 
the initial synovitis, the T cell-mediated auto-immune response may have no or only 
limited relevance in established human RA where the joint inflammation may have 
become self-perpetuating. 
 In summary, the current trial was the first large clinical investigation into the 
efficacy of a fully human, recombinant, protein (HC gp-39, Org 39141) administered via 
the nasal route with the purpose to induce immunological tolerance. As numerous 
reasons may have led to lack-of-efficacy, the future of tolerance induction therapy 
seems rather uncertain. 
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